Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Siponimod

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 283,739Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    NICE recommends siponimod for treating secondary progressive MS
    NICE recommends siponimod for treating secondary progressive MS

    15 Oct 2020

    // PHARMAFILE

    http://www.pharmafile.com/news/561675/nice-recommends-siponimod-treating-secondary-progressive-ms

    PHARMAFILE
    15 Oct 2020
    Share Share
    Novartis data show early treatment with Mayzent delays disability progression
    Novartis data show early treatment with Mayzent delays disability progression

    14 Sep 2020

    // PRESS RELEASE

    https://www.novartis.com/news/media-releases/novartis-data-show-early-treatment-mayzent-siponimod-delays-disability-progression-and-show-benefits-cognitive-performance-patients-secondary-progressive

    PRESS RELEASE
    14 Sep 2020
    Share Share
    Novartis Responds to NICE Decision on Siponimod
    Novartis Responds to NICE Decision on Siponimod

    25 Jun 2020

    // PHARMTECH

    http://www.pharmtech.com/novartis-responds-nice-decision-siponimod

    PHARMTECH
    25 Jun 2020
    Share Share
    China approves Novartis' multiple sclerosis treatment Mayzent
    China approves Novartis' multiple sclerosis treatment Mayzent

    12 May 2020

    // Roxanne Liu REUTERS

    https://www.reuters.com/article/us-novartis-china-multiple-sclerosis/china-approves-novartis-multiple-sclerosis-treatment-mayzent-idUSKBN22L0C6?feedType=RSS&feedName=healthNews

    Roxanne Liu REUTERS
    12 May 2020
    Share Share
    Novartis Says New Mayzent Data Shows Sustained Effect In Delaying Disability
    Novartis Says New Mayzent Data Shows Sustained Effect In Delaying Disability

    22 Apr 2020

    // REUTERS

    https://www.reuters.com/article/brief-novartis-says-new-mayzent-data-sho/brief-novartis-says-new-mayzent-data-shows-sustained-effect-in-delaying-disability-idUSFWN2C81DY

    REUTERS
    22 Apr 2020
    Share Share
    European Commission approves nintedanib for the treatment of systemic sclerosi
    European Commission approves nintedanib for the treatment of systemic sclerosi

    21 Apr 2020

    // APNEWS

    https://apnews.com/Business Wire/00755474c304495887802ac0a1206b9e

    APNEWS
    21 Apr 2020
    Share Share